Corcept Therapeutics (NASDAQ:CORT) Insider Sells $1,036,600.00 in Stock

Key Points

• Insider William Guyer sold 20,000 shares on May 5 at an average price of $51.83 for a total of $1,036,600, leaving him with 2,231 shares — an ~89.96% reduction in his ownership after multiple sales earlier this year.
• Corcept missed Q1 estimates with EPS of -$0.30 and revenue of $164.9M, but the company raised its 2026 outlook and highlighted encouraging ALS data, prompting analyst upgrades and a consensus rating of Moderate Buy with an average target of $74.67.

Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) insider William Guyer sold 20,000 shares of the business's stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $51.83, for a total transaction of $1,036,600.00. Following the completion of the transaction, the insider directly owned 2,231 shares of the company's stock, valued at approximately $115,632.73. This represents a 89.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

William Guyer also recently made the following trade(s):

• On Tuesday, April 7th, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $40.97, for a total transaction of $819,400.00.
• On Friday, March 20th, William Guyer sold 11,767 shares of Corcept Therapeutics stock. The stock was sold at an average price of $36.01, for a total transaction of $423,729.67.
• On Wednesday, March 4th, William Guyer sold 8,233 shares of Corcept Therapeutics stock. The stock was sold at an average price of $35.99, for a total transaction of $296,305.67.

Corcept Therapeutics Stock Performance

Shares of NASDAQ CORT traded down $1.10 during trading on Thursday, reaching $51.05. The company had a trading volume of 1,117,065 shares, compared to its average volume of 1,890,212. Corcept Therapeutics Incorporated has a 52 week low of $28.66 and a 52 week high of $91.00. The stock has a market cap of $5.48 billion, a PE ratio of 145.86 and a beta of 0.36. The business's 50 day moving average price is $39.80 and its 200-day moving average price is $53.99.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last announced its earnings results on Thursday, April 30th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.19). Corcept Therapeutics had a return on equity of 7.40% and a net margin of 6.14%.The company had revenue of $164.90 million during the quarter, compared to the consensus estimate of $185.83 million. During the same period in the prior year, the firm posted $0.17 earnings per share. The company's revenue was up 4.9% on a year-over-year basis. Equities analysts anticipate that Corcept Therapeutics Incorporated will post 0.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on CORT shares. Canaccord Genuity Group boosted their target price on shares of Corcept Therapeutics from $100.00 to $110.00 and gave the stock a "buy" rating in a research note on Thursday, March 26th. HC Wainwright lifted their price target on shares of Corcept Therapeutics from $60.00 to $75.00 and gave the stock a "buy" rating in a research report on Monday. Wolfe Research upgraded shares of Corcept Therapeutics from an "underperform" rating to a "peer perform" rating in a research report on Thursday, March 26th. Piper Sandler lifted their price target on shares of Corcept Therapeutics from $73.00 to $88.00 and gave the stock an "overweight" rating in a research report on Friday, May 1st. Finally, Zacks Research upgraded shares of Corcept Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $74.67.

Key Headlines Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Company raised its 2026 outlook and highlighted encouraging ALS data, which drove an intraday rally as investors re‑rate the pipeline and longer‑term growth prospects. Corcept Therapeutics (CORT) Is Up 11.9% After Q1 Loss, Higher 2026 Outlook And ALS Data - Has The Bull Case Changed?
• Positive Sentiment: HC Wainwright materially raised near‑ and long‑term EPS forecasts and maintained a "Buy" rating with a $75 price target — upgrades include FY2026 to $0.76 (from $0.26 previously) and FY2030 to $8.60 — signaling dealer confidence in revenue growth and margin expansion over time.
• Neutral Sentiment: Zacks Research upgraded CORT from "strong sell" to "hold," which reduces downside stigma but is not a bullish endorsement; this may modestly stabilize investor sentiment. Zacks.com
• Neutral Sentiment: Investors can review the full Q1 earnings call transcript for management commentary on sales trends, cost structure and the ALS program for more context; the transcript may influence near‑term trading as details are parsed. Corcept Therapeutics Q1 2026 Earnings Call Transcript
• Negative Sentiment: Q1 results disappointed: EPS of -$0.30 missed the -$0.11 consensus and revenue of $164.9M fell short of ~$185.8M estimates — these misses highlight near‑term growth pressure and explain cautious positioning despite positive pipeline/newsflow.

Institutional Investors Weigh In On Corcept Therapeutics

Institutional investors have recently modified their holdings of the business. Advisory Services Network LLC acquired a new stake in shares of Corcept Therapeutics during the 3rd quarter worth approximately $25,000. Clearstead Advisors LLC grew its holdings in Corcept Therapeutics by 163.6% during the third quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company's stock valued at $26,000 after purchasing an additional 193 shares during the period. Hantz Financial Services Inc. grew its holdings in Corcept Therapeutics by 598.5% during the third quarter. Hantz Financial Services Inc. now owns 461 shares of the biotechnology company's stock valued at $38,000 after purchasing an additional 395 shares during the period. Larson Financial Group LLC grew its holdings in Corcept Therapeutics by 2,326.3% during the third quarter. Larson Financial Group LLC now owns 461 shares of the biotechnology company's stock valued at $38,000 after purchasing an additional 442 shares during the period. Finally, Gould Capital LLC grew its holdings in Corcept Therapeutics by 50.0% during the third quarter. Gould Capital LLC now owns 600 shares of the biotechnology company's stock valued at $50,000 after purchasing an additional 200 shares during the period. Institutional investors and hedge funds own 93.61% of the company's stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company's scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company's flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing's syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.